Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy

By sjmartinez • June 14, 2024

Kohrman NM, Wlodarczyk JR, Ding L, McAndrew NP, Algaze SD, Cologne KG, Lee SW, Koller SE. Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy. Dis Colon Rectum. 2024 Jul 1;67(7):920-928. doi: 10.1097/DCR.0000000000003261. Epub 2024 Mar 18. PMID: 38498775.

Tags: Hematology/Oncology, Publications

PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma

Kumar S, Benavides-Serrato A, Saunders JT, Nishimura RN, Gera JF. PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.[...]

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases

Juarez Casillas JE, Nezafat M, Benitez CM, Rzechowski K, Kane N, Sjöstrand K, Anand A, Sonni I, Berenji GR, Duriseti S, Rettig MB, Nickols NG.[...]

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf[...]